CMV

COMMUNIQUÉS West-GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
11/08/2025
Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approval Capricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially [...]
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
11/08/2025
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategy EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, [...]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025
11/08/2025
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its [...]
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
11/08/2025
Reiterating timelines for FDA submission in 2025 Transplant clinical trial has attracted leading transplant hospitals Booked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping [...]
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/08/2025
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
11/08/2025
Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume [...]
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
11/08/2025
Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency (EMA) for [...]
Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights
11/08/2025
FDA PDUFA goal date of   August   15 , 2025, for TNX ‑ 102   SL for fibromyalgia: if approved by FDA, TNX ‑ 102   SL would be the first new drug for fibromyalgia in more than 16   years   In   June   2025, the Company [...]
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
11/08/2025
$5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN [...]
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
11/08/2025
Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced [...]
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
11/08/2025
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million [...]
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
11/08/2025
HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease [...]
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
11/08/2025
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and [...]
Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
11/08/2025
MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public [...]
Anteris Announces Results for the Second Quarter of 2025
11/08/2025
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results
11/08/2025
Posts Positive Organic Growth and Adjusted EBITDA ‎ 1 of 23.5% of Revenue CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“ Quipt ” or the “ Company ”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based [...]
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
12/08/2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“ Revive ” or the “ Company ”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative [...]
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
11/08/2025
Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2. Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five [...]
Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients
11/08/2025
Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health , a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 [...]

Pages